Persistence with biologic therapies in the medicare coverage gap

Leonardo Tamariz, Claudia L. Uribe, Jiacong Luo, John W. Hanna, Daniel E. Ball, Kelly Krohn, Eric S. Meadows

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives: To describe persistence with teriparatide and other biologic therapies in Medicare Part D plans with and without a coverage gap. Study Design: Retrospective (2006) cohort study of Medicare Part D prescription drug plan beneficiaries from a large benefits company. Two plans with a coverage gap (defined as "basic") were combined and compared with a single plan with coverage for generic and branded medications (defined as "complete"). Methods: Patients taking alendronate (nonbiologic comparator), teriparatide, etanercept, adalimumab, interferon ®-1a, or glatiramer acetate were selected for the study. For patients with complete coverage, equivalent financial thresholds were used to define the "gap." The definition of discontinuation was failure to fill the index prescription after reaching the gap. Results: For alendronate, 27% of 133,260 patients had enrolled in the complete plan. Patients taking biologic therapies had more commonly enrolled in complete plans: teriparatide (66% of 6221), etanercept (58% of 1469), adalimumab (52% of 824), interferon &βετα;-1a (60% of 438), and glatiramer acetate (53% of 393). For patients taking either alendronate or teriparatide, discontinuation rates were higher in the basic, versus complete, plan (adjusted odds ratios, 2.02 and 3.56, respectively). Discontinuation did not significantly vary by plan type for etanercept, adalimumab, interferon β-1a, or glatiramer acetate. Conclusions: For patients who reached the coverage gap, discontinuation was more likely for patients taking osteoporosis (OP) medication. Not having a coverage gap was associated with improved persistence with OP treatment.

Original languageEnglish
Pages (from-to)753-759
Number of pages7
JournalAmerican Journal of Managed Care
Volume17
Issue number11
StatePublished - Nov 1 2011

Fingerprint

Biological Therapy
Medicare
Teriparatide
Alendronate
Medicare Part D
Interferons
Osteoporosis
Prescription Drugs
Prescriptions
Cohort Studies
Retrospective Studies
Odds Ratio
Glatiramer Acetate
Etanercept
Adalimumab

ASJC Scopus subject areas

  • Health Policy

Cite this

Tamariz, L., Uribe, C. L., Luo, J., Hanna, J. W., Ball, D. E., Krohn, K., & Meadows, E. S. (2011). Persistence with biologic therapies in the medicare coverage gap. American Journal of Managed Care, 17(11), 753-759.

Persistence with biologic therapies in the medicare coverage gap. / Tamariz, Leonardo; Uribe, Claudia L.; Luo, Jiacong; Hanna, John W.; Ball, Daniel E.; Krohn, Kelly; Meadows, Eric S.

In: American Journal of Managed Care, Vol. 17, No. 11, 01.11.2011, p. 753-759.

Research output: Contribution to journalArticle

Tamariz, L, Uribe, CL, Luo, J, Hanna, JW, Ball, DE, Krohn, K & Meadows, ES 2011, 'Persistence with biologic therapies in the medicare coverage gap', American Journal of Managed Care, vol. 17, no. 11, pp. 753-759.
Tamariz L, Uribe CL, Luo J, Hanna JW, Ball DE, Krohn K et al. Persistence with biologic therapies in the medicare coverage gap. American Journal of Managed Care. 2011 Nov 1;17(11):753-759.
Tamariz, Leonardo ; Uribe, Claudia L. ; Luo, Jiacong ; Hanna, John W. ; Ball, Daniel E. ; Krohn, Kelly ; Meadows, Eric S. / Persistence with biologic therapies in the medicare coverage gap. In: American Journal of Managed Care. 2011 ; Vol. 17, No. 11. pp. 753-759.
@article{360d178230104fba8e04555b1e06f8ff,
title = "Persistence with biologic therapies in the medicare coverage gap",
abstract = "Objectives: To describe persistence with teriparatide and other biologic therapies in Medicare Part D plans with and without a coverage gap. Study Design: Retrospective (2006) cohort study of Medicare Part D prescription drug plan beneficiaries from a large benefits company. Two plans with a coverage gap (defined as {"}basic{"}) were combined and compared with a single plan with coverage for generic and branded medications (defined as {"}complete{"}). Methods: Patients taking alendronate (nonbiologic comparator), teriparatide, etanercept, adalimumab, interferon {\circledR}-1a, or glatiramer acetate were selected for the study. For patients with complete coverage, equivalent financial thresholds were used to define the {"}gap.{"} The definition of discontinuation was failure to fill the index prescription after reaching the gap. Results: For alendronate, 27{\%} of 133,260 patients had enrolled in the complete plan. Patients taking biologic therapies had more commonly enrolled in complete plans: teriparatide (66{\%} of 6221), etanercept (58{\%} of 1469), adalimumab (52{\%} of 824), interferon &βετα;-1a (60{\%} of 438), and glatiramer acetate (53{\%} of 393). For patients taking either alendronate or teriparatide, discontinuation rates were higher in the basic, versus complete, plan (adjusted odds ratios, 2.02 and 3.56, respectively). Discontinuation did not significantly vary by plan type for etanercept, adalimumab, interferon β-1a, or glatiramer acetate. Conclusions: For patients who reached the coverage gap, discontinuation was more likely for patients taking osteoporosis (OP) medication. Not having a coverage gap was associated with improved persistence with OP treatment.",
author = "Leonardo Tamariz and Uribe, {Claudia L.} and Jiacong Luo and Hanna, {John W.} and Ball, {Daniel E.} and Kelly Krohn and Meadows, {Eric S.}",
year = "2011",
month = "11",
day = "1",
language = "English",
volume = "17",
pages = "753--759",
journal = "American Journal of Managed Care",
issn = "1088-0224",
publisher = "Ascend Media",
number = "11",

}

TY - JOUR

T1 - Persistence with biologic therapies in the medicare coverage gap

AU - Tamariz, Leonardo

AU - Uribe, Claudia L.

AU - Luo, Jiacong

AU - Hanna, John W.

AU - Ball, Daniel E.

AU - Krohn, Kelly

AU - Meadows, Eric S.

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Objectives: To describe persistence with teriparatide and other biologic therapies in Medicare Part D plans with and without a coverage gap. Study Design: Retrospective (2006) cohort study of Medicare Part D prescription drug plan beneficiaries from a large benefits company. Two plans with a coverage gap (defined as "basic") were combined and compared with a single plan with coverage for generic and branded medications (defined as "complete"). Methods: Patients taking alendronate (nonbiologic comparator), teriparatide, etanercept, adalimumab, interferon ®-1a, or glatiramer acetate were selected for the study. For patients with complete coverage, equivalent financial thresholds were used to define the "gap." The definition of discontinuation was failure to fill the index prescription after reaching the gap. Results: For alendronate, 27% of 133,260 patients had enrolled in the complete plan. Patients taking biologic therapies had more commonly enrolled in complete plans: teriparatide (66% of 6221), etanercept (58% of 1469), adalimumab (52% of 824), interferon &βετα;-1a (60% of 438), and glatiramer acetate (53% of 393). For patients taking either alendronate or teriparatide, discontinuation rates were higher in the basic, versus complete, plan (adjusted odds ratios, 2.02 and 3.56, respectively). Discontinuation did not significantly vary by plan type for etanercept, adalimumab, interferon β-1a, or glatiramer acetate. Conclusions: For patients who reached the coverage gap, discontinuation was more likely for patients taking osteoporosis (OP) medication. Not having a coverage gap was associated with improved persistence with OP treatment.

AB - Objectives: To describe persistence with teriparatide and other biologic therapies in Medicare Part D plans with and without a coverage gap. Study Design: Retrospective (2006) cohort study of Medicare Part D prescription drug plan beneficiaries from a large benefits company. Two plans with a coverage gap (defined as "basic") were combined and compared with a single plan with coverage for generic and branded medications (defined as "complete"). Methods: Patients taking alendronate (nonbiologic comparator), teriparatide, etanercept, adalimumab, interferon ®-1a, or glatiramer acetate were selected for the study. For patients with complete coverage, equivalent financial thresholds were used to define the "gap." The definition of discontinuation was failure to fill the index prescription after reaching the gap. Results: For alendronate, 27% of 133,260 patients had enrolled in the complete plan. Patients taking biologic therapies had more commonly enrolled in complete plans: teriparatide (66% of 6221), etanercept (58% of 1469), adalimumab (52% of 824), interferon &βετα;-1a (60% of 438), and glatiramer acetate (53% of 393). For patients taking either alendronate or teriparatide, discontinuation rates were higher in the basic, versus complete, plan (adjusted odds ratios, 2.02 and 3.56, respectively). Discontinuation did not significantly vary by plan type for etanercept, adalimumab, interferon β-1a, or glatiramer acetate. Conclusions: For patients who reached the coverage gap, discontinuation was more likely for patients taking osteoporosis (OP) medication. Not having a coverage gap was associated with improved persistence with OP treatment.

UR - http://www.scopus.com/inward/record.url?scp=81455128911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81455128911&partnerID=8YFLogxK

M3 - Article

C2 - 22084895

AN - SCOPUS:81455128911

VL - 17

SP - 753

EP - 759

JO - American Journal of Managed Care

JF - American Journal of Managed Care

SN - 1088-0224

IS - 11

ER -